Am­per­sand Bio­med­i­cines, a biotech work­ing on med­i­cines “sim­i­lar in prin­ci­ple” to an­ti­body-drug con­ju­gates, has se­cured $65 mil­lion in a Se­ries B round.

Just as a map shows you how to reach a destination in the real world, Ampersand Biomedicines’ map of tissues of the human body shows where a drug should go in the biological one. Now the startup ...

Ampersand’s Series B funding will fuel the continued development of its computationally powered Address, Navigate, Determine (AND)™ Platform to program AND-Body™ Therapeutics, a new category ...

In the 1940s, it was possible to catch a Bakerloo line train from Ampersand station, even though no such station officially existed. Ampersand station (c) ianVisits The station was officially called ...